A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation.

Malnutrition is a prevalent condition in Cystic Fibrosis (CF) and can result in worsening of pulmonary function and other comorbidities. Cystic fibrosis transmembrane regulator (CFTR) modulator therapies are improving the CF-related care and outcomes. Body Mass Index (BMI) is the most commonly used parameter to assess nutritional status, albeit it is a very unspecific indicator. Hence, current guidelines recommend body composition analysis as a part of nutritional assessment. The aim of our study was to evaluate the impact of elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) treatment on body composition and respiratory function.

Source: Clinical Nutrition - October 17, 2023 Category: Nutrition Authors: Carolina Knott-Torcal, Fernando Sebasti án-Valles, Rosa María Girón Moreno, José Carlos Martín- Adán, Jessica Jiménez-Díaz, Mónica Marazuela, Nuria Sánchez de la Blanca, Raúl Fernández-Contreras, Alfonso Arranz-Martín Tags: Original article Source Type: research